Literature DB >> 28750299

Prolonged activation of the coagulation system during in vitro fertilization cycles.

Yoni Cohen1, Togas Tulandi2, Benny Almog3, Eyal Zohav3, Varda Deutsch4, Ariel Many3, Ami Amit3, Aviad Cohen5.   

Abstract

OBJECTIVE: To investigate coagulation system changes during an in-vitro fertilization (IVF) cycle using Thromboelastogram (TEG) that enables analysis of the elastic properties of whole blood samples and provides a global assessment of the hemostatic function. STUDY
DESIGN: A prospective study. TEG indices were evaluated in 23 women who underwent controlled ovarian stimulation for IVF at four points in time: 1. At the beginning of the cycle (corresponding to the lowest levels of E2), 2. On the day of hCG administration (maximal stimulation with highest E2 levels), 3. On the day of ovum pickup and 4. At the first pregnancy test (approximately 14days after ovum pickup). The main outcome measures were TEG indices including R-time (time until initial fibrin formation), K-time (time until a 20mm amplitude is achieved), α angle (the rate of clot formation), Maximum Amplitude (MA, strength of the fibrin clot), Coagulation Index (CI, calculated overall indicator of coagulation) and LY30 (the decrease in graph amplitude).
RESULTS: R, K, α angle, MA and CI before hCG administration and at the time of the first pregnancy test were significantly higher compared to the baseline measurement before gonadotropins administration. No correlation was found between E2 and TEG indices.
CONCLUSION: Ovarian stimulation is associated with prolonged increased coagulability that extends after the time of maximal ovarian stimulation. The lack of association between E2 levels and TEG indices suggest that additional factors may play a role in the pathogenesis of increased coagulability in women with ovarian stimulation.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Hypercoagulability; Ovarian hyperstimulation; Thromboelastogram; Thrombosis

Mesh:

Year:  2017        PMID: 28750299     DOI: 10.1016/j.ejogrb.2017.07.021

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  3 in total

1.  Diagnosis and Treatment Before Assisted Reproductive Treatments. Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Register Number 015-085, February 2019) - Part 2, Hemostaseology, Andrology, Genetics and History of Malignant Disease.

Authors:  Bettina Toth; Dunja Maria Baston-Büst; Hermann M Behre; Alexandra Bielfeld; Michael Bohlmann; Kai Bühling; Ralf Dittrich; Maren Goeckenjan; Katharina Hancke; Sabine Kliesch; Frank-Michael Köhn; Jan Krüssel; Ruben Kuon; Jana Liebenthron; Frank Nawroth; Verena Nordhoff; Germar-Michael Pinggera; Nina Rogenhofer; Sabine Rudnik-Schöneborn; Hans-Christian Schuppe; Andreas Schüring; Vanadin Seifert-Klauss; Thomas Strowitzki; Frank Tüttelmann; Kilian Vomstein; Ludwig Wildt; Tewes Wischmann; Dorothea Wunder; Johannes Zschocke
Journal:  Geburtshilfe Frauenheilkd       Date:  2019-12-11       Impact factor: 2.915

2.  GnRH Antagonist Protocol Enhances Coagulation During Controlled Ovarian Stimulation for IVF.

Authors:  Magdalena Piróg; Olga Kacalska-Janssen; Robert Jach; Jakub Wyroba; Bartosz Chrostowski; Michał Ząbczyk; Joanna Natorska
Journal:  Reprod Sci       Date:  2022-07-12       Impact factor: 2.924

3.  Primary anetoderma in a woman after ovarian stimulations for in vitro fertilization program.

Authors:  Salvatore Bellanca; Maria Letizia Musumeci; Fabio Catalano; Rossella Cannarella; Carmelo Liuzzo; Anna Paola Capra; Giuseppe Micali
Journal:  JAAD Case Rep       Date:  2019-05-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.